A CDNA PROBE FOR SURFACTANT APOPROTEIN FROM HUMAN LUNG

在肺泡中，空气-液体界面处的表面张力 被称为肺动脉的脂蛋白复合物降低 表面活性 肺表面活性物质的重要性在以下方面变得明显： 缺乏这种脂蛋白复合物的早产儿， 呼吸窘迫综合征（RDS）。 研究表明，表面活性剂 蛋白质在肺中可能具有重要的功能作用， 表面活性剂的吸附和扩展运动的速度从次相的 水溶液。 为了更好地了解表面活性剂相关蛋白在细胞凋亡中的作用， 肺表面活性物质的功能，研究其在肺功能中的作用具有重要意义。 这些蛋白质的调节和生理学。 为了解决这些问题， 一种方法是开发针对这些蛋白质的特异性探针。 我们提出 在Lambdagt 11载体中制备互补DNA（cDNA）表达库 从人肺的mRNA。 我们将用一种特异性抗血清对银行进行筛查 识别表面活性蛋白的初级翻译产物 在我们的实验室里就可以得到。 通过这次筛选我们将能够 鉴定编码表面活性剂相关蛋白的mRNA的cDNA克隆。 随后，我们计划使用这些阳性cDNA克隆作为探针， 确定这些蛋白质的分子组成（即数量和 编码这些蛋白质的mRNA序列的大小）。 此外，我们将 获得对编码这些蛋白质的每种mRNA具有特异性的cDNA探针， 将有助于对每个分子组分进行调节研究 这些蛋白质。 这种探针的可用性也将允许a）结构研究 这些蛋白质的基因可以提供特定的指示剂， RDS的产前诊断B）这些表达的调节研究 c）体内和体外 功能研究，以更好地了解这些蛋白质在 功能表面活性剂和可能的治疗研究。

In the alveoli of the lung the surface tension at the air-liquid interface is lowered by the presence of a lipoprotein complex called pulmonary surfactant. The importance of pulmonary surfactant becomes evident in the prematurely born infants deficient in this lipoprotein complex who manifect respiratory distress syndrome (RDS). Studies suggest that surfactant proteins may have an important functional role in the lung by enhancing the rate of surfactant adsorption and spreading movement from the hypophase of aqueous solutions. To better understand the role of the surfactant-associated proteins in the function of pulmonary surfactant, it is of obvious importance to study the regulation and physiology of these proteins. To address these questions, ones approach is to develop specific probes for these proteins. We propose to prepare a complementary DNA (cDNA) expression bank in Lambdagt11 vector from human lung mRNA. We will screen the bank with a specific antiserum that recognizes the primary translation products of the surfactant proteins that is available in our laboratory. With this screening we will be able to identify cDNA clones for mRNAs encoding surfactant-associated proteins. Subsequently we plan to use these positive cDNA clones as probes to identify the molecular components of these proteins (i.e. the number and size of mRNA sequences coding for these proteins). In addition we will obtain cDNA probes specific for each mRNA coding for these proteins, which will be useful to carry out regulatory studies for each molecular component of these proteins. The availability of such probes will also permit a) structural studies of the gene(s) of these proteins that may provide a specific indicator for prenatal diagnosis of RDS b) regulatory studies of the expression of these proteins under normal and disease conditions c) in vivo and in vitro functional studies to better understand the role of these proteins in the function to surfactant and possibly therapeutic studies.